This video is for instructional purposes only. The
vaccine and diluent vials shown in this video may differ
in appearance from actual vials of VARIVAX and/or its
accompanying diluent.
Indications and Dosing
VARIVAX is indicated for vaccination against varicella in individuals 12
months of age and older.
—
Children 12 months to 12 years of age should receive a 0.5-mL dose
administered subcutaneously; if a second 0.5-mL dose is administered, it should
be given a minimum of 3 months later.
—
Adolescents and adults 13 years of age and older should receive a
0.5-mL
dose administered subcutaneously at elected date and a second 0.5-mL dose 4 to
8 weeks later.1
Select Safety Information
VARIVAX is contraindicated in certain individuals, including those with: a
history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactoid
reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or
other malignant neoplasms affecting the bone marrow or lymphatic systems; an
immunodeficient condition or receiving immunosuppressive therapy; active, untreated
tuberculosis; active febrile illness; or those who are pregnant.
In children, adolescents, and adults monitored for up to 42 days, the adverse
effects most frequently reported were as follows: fever, injection-site complaints,
varicella-like rash (injection site), and varicella-like rash (generalized).
The duration of protection of VARIVAX is unknown; however, long-term efficacy
studies have demonstrated continued protection up to 10 years after vaccination.
Vaccination with VARIVAX may not result in protection of all healthy, susceptible
children, adolescents, and adults.
